99,200 Shares in Catalent, Inc. (NYSE:CTLT) Acquired by Athos Capital Ltd

Athos Capital Ltd purchased a new stake in shares of Catalent, Inc. (NYSE:CTLT - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 99,200 shares of the company's stock, valued at approximately $6,009,000. Catalent accounts for approximately 1.9% of Athos Capital Ltd's investment portfolio, making the stock its 8th largest position. Athos Capital Ltd owned 0.05% of Catalent as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of CTLT. Dynamic Technology Lab Private Ltd purchased a new stake in Catalent in the 3rd quarter worth approximately $1,131,000. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Catalent by 3.7% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company's stock worth $24,550,000 after purchasing an additional 14,373 shares in the last quarter. Quest Partners LLC raised its position in shares of Catalent by 289.8% during the 3rd quarter. Quest Partners LLC now owns 49,300 shares of the company's stock valued at $2,986,000 after purchasing an additional 36,652 shares during the period. Swedbank AB purchased a new position in shares of Catalent during the 1st quarter valued at $1,659,000. Finally, Natixis Advisors LLC bought a new position in Catalent in the 3rd quarter worth $1,287,000.

Catalent Price Performance

CTLT traded up $0.32 during trading hours on Monday, hitting $61.43. The company's stock had a trading volume of 1,974,060 shares, compared to its average volume of 2,030,668. The stock has a market cap of $11.15 billion, a price-to-earnings ratio of -27.04, a P/E/G ratio of 2.43 and a beta of 1.16. The business's 50-day moving average price is $59.90 and its 200-day moving average price is $58.51. The company has a current ratio of 2.51, a quick ratio of 1.96 and a debt-to-equity ratio of 1.38. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.50.

Catalent (NYSE:CTLT - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter last year, the firm earned ($0.10) earnings per share. The business's quarterly revenue was up 4.2% on a year-over-year basis. Sell-side analysts expect that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Insider Buying and Selling at Catalent

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of the business's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the transaction, the director now owns 10,835 shares in the company, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Mcerlane sold 1,994 shares of the firm's stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $59.97, for a total transaction of $119,580.18. Following the completion of the sale, the insider now owns 36,304 shares of the company's stock, valued at $2,177,150.88. This trade represents a 5.21 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,114 shares of company stock worth $305,931 over the last ninety days. Company insiders own 0.31% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Baird R W downgraded Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. StockNews.com downgraded Catalent from a "hold" rating to a "sell" rating in a research note on Friday, November 22nd. Robert W. Baird reaffirmed a "neutral" rating and set a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Finally, William Blair reissued a "market perform" rating on shares of Catalent in a report on Tuesday, September 3rd. One equities research analyst has rated the stock with a sell rating and seven have issued a hold rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $63.40.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.